ЛИТЕРАТУРА
1. Кондрашин С.А., Пашкова И.Л., Майорова Е.М. Ангиография и артериально-стимулированный забор крови в топической диагностике органического гиперинсулинизма // Диагностическая и интервенционная радиология. 2008. T. 2, № 1. C. 13-28.
2. Atema J.J., Jilesen A.P., Busch O.R., van Gulik T.M., Gouma D.J., Nieveen van Dijkum E.J. Pancreatic fistulae after pancreatic resections for neuroendocrine tumours compared with resections for other lesions // HPB (Oxford). 2015. Vol. 17, N 1. P. 38-45.
3. Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States // JAMA Oncol. 2017. Vol. 3, N 10. P. 1335-1342.
4. Egorov A.V., Musaev G., Kondrashin S.A., Khorobrykh T.V., Anisimova O.V., Parnova V.A. [Prognostic factors of the immediate results of surgical treatment of organic hyperinsulinism] // Khirurgiia (Mosk.). 2011. Vol. 6. P. 60-65.
5. Falconi M., Plockinger U., Kwekkeboom D.J., Manfredi R., Korner M., Kvols L. et l.; Frascati Consensus Conference, European Neuroendocrine Tumor Society. Welldifferentiated pancreatic nonfunctioning tumors/carcinoma // Neuroendocrinology. 2006. Vol. 84, N 3. P. 196-211.
6. Fan J.H., Zhang Y.Q., Shi S.S., Chen Y.J., Yuan X.H., Jiang L.M. et al. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china // Oncotarget. 2017. Vol. 8, N 42. P. 71 699-71 708.
7. Fendrich V., Merz M.K., Waldmann J., Langer P., Heverhagen A.E., Dietzel K. et al. Neuroendocrine pancreatic tumors are risk factors for pancreatic fistula after pancreatic surgery // Dig. Surg. 2011. Vol. 28, N 4. P. 263-269.
8. Goh B.K., Tan Y.M., Chung Y.F., Cheow P.C., Ong H.S., Chan W.H. et al. Critical ppraisal of 232 consecutive distal pancreatectomies with emphasis on risk factors, utcome, and management of the postoperative pancreatic fistula: a 21-year experience at a single institution // Arch. Surg. 2008. Vol. 143, N 10. P. 956-965.
9. Ito T., Igarashi H., Jensen R.T. Zollinger-Ellison syndrome: recent advances and ontroversies // Curr. Opin. Gastroenterol. 2013. Vol. 29, N 6. P. 650-661.
10. Karabulut K., Akyildiz H.Y., Lance C., Aucejo F., McLennan G., Agcaoglu O. et al. Multimodality treatment of neuroendocrine liver metastases // Surgery. 2011. Vol. 150, N 2. P. 316-325.
11. Kim J.H., Eun H.W., Kim Y.J., Lee J.M., Han J.K. et al. Pancreatic neuroendocrine umour (PNET): staging accuracy of MDCT and its diagnostic performance for the ifferentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma // Eur. Radiol. 2016. Vol. 26, N 5. P. 1338-1347.
12. Luo Y., Pan Q., Yao S., Yu M., Wu W., Xue H. et al. Glucagon-like peptide-1 receptor PET/CT with 68Ga-NOTA-exendin-4 for detecting localized insulinoma: a prospective cohort study // J. Nucl. Med. 2016. Vol. 57, N 5. C. 715-720.
13. Modlin I.M., Oberg K., Chung D.C., Jensen R.T., de Herder W.W., Thakker R.V. et al. Gastroenteropancreatic neuroendocrine tumours // Lancet Oncol. 2008. Vol. 9, N 1. P. 61-72.
14. Niederle B., Pape U.F., Costa F., Gross D., Kelestimur F., Knigge U. et al.; Vienna onsensus Conference participants. ENETS Consensus Guidelines Update for euroendocrine Neoplasms of the Jejunum and Ileum // Neuroendocrinology. 2016. Vol. 103, N 2. P. 125-138.
15. Okabayashi T., Kobayashi M., Nishimori I., Sugimoto T., Onishi S., Hanazaki K. isk factors, predictors and prevention of pancreatic fistula formation after ancreatoduodenectomy // J. Hepatobiliary Pancreat. Surg. 2007. Vol. 14, N 6. C. 557-563.
16. Partelli S., Bartsch D.K., Capdevila J., Chen J., Knigge U., Niederle B., Antibes onsensus Conference participants. ENETS Consensus Guidelines for standard of care n neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine umours // Neuroendocrinology. 2017. Vol. 105, N 3. P. 255-265.
17. Trofimiuk-Muldner M., Lewkowicz E., Wysocka K., Pach D., Kieltyka A., Stefanska A. et al. Epidemiology of gastroenteropancreatic neuroendocrine neoplasms in Krakow and Krakow district in 2007-2011 // Endokrynol. Pol. 2017. Vol. 68, N 1. P. 42-46.
18. Ulla Rocha J.L., Salgado A., Sardina Ferreiro R., Fernandez Catalina P., Gallardo E. Neuroendocrine gastroenteropancreatic tumors: where are we? // Surg. Laparosc. Endosc. Percutan. Tech. 2017. Vol. 27, N 1. P. 36-41.
19. van Heek N.T., Kuhlmann K.F., Scholten R.J., de Castro S.M., Busch O.R., van Gulik T.M. et al. Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands // Ann. Surg. 2005. Vol. 242, N 6. P. 781-788.
20. Versari A., Camellini L., Carlinfante G., Frasoldati A., Nicoli F., Grassi E. et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study // Clin. Nucl. Med. 2010. Vol. 35, N 5. P. 321-328.
21. Yadav S., Sharma P., Zakalik D. Comparison of demographics, tumor characteristics, and survival between pancreatic adenocarcinomas and pancreatic neuroendocrine tumors: a population-based study // Am. J. Clin. Oncol. 2018. Vol. 41, N 5. P. 485-491.